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endocytosisChronic hyperglycaemia during diabetes leads to non-enzymatic glycation of proteins to form advanced
glycation end products (AGEs) that contribute to nephropathy. In diabetes, renal Na+ K+ ATPase (NKA)
activity is downregulated and phosphoinositide metabolism is upregulated. We examined the effects of AGEs
on NKA activity in porcine LLC-PK1 and human HK2 proximal tubule epithelial cells. AGE-BSA increased
cellular phosphoinositol 4,5 bisphosphate (PIP2) production as determined by immunoﬂuorescence
microscopy and thin layer chromatography. AGE-BSA (40 μM) induced 3H-arachidonic acid release and
reactive oxygen species (ROS) production via cytosolic phospholipase A2 (cPLA2) activation. Within minutes,
AGE-BSA signiﬁcantly inhibited NKA surface expression and activity in a dose- and time-dependent manner
as determined by immunoﬂuorescence staining and [86Rb+] uptake, respectively, suggesting AGEs inhibit
NKA by stimulating its endocytosis. The AGE-BSA-induced decrease in cell surface NKA was reversed by a
cPLA2α inhibitor, neomycin, a PIP2 inhibitor, and PP2, a Src inhibitor. AGE-BSA increased binding of NKA to
the α-adaptin but not β2- or μ2-adaptin subunits of the AP-2 clathrin pit adaptor complex. Transfection of
HK2 cells with PIP5Kγ siRNA prevented AGE-BSA inhibition of NKA activity. AGEs may stimulate PIP5Kγ to
increase PIP2 production, which may enhance AP-2 localisation to clathrin pits, increase clathrin pit
formation, enhance NKA cargo recognition by AP-2 and/or stimulate cPLA2α activity. These results suggest
AGEs modulate arachidonic acid and phosphoinositide metabolism to inhibit NKA via clathrin-mediated
endocytosis. Elucidation of new intracellular AGE signaling pathways may lead to improved therapies for
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Nonenzymatic glycation of proteins, lipids and nucleic acids
resulting in the accumulation of advanced glycation end products
(AGEs) correlates with the development of chronic diabetic complica-
tions such as retinopathy, nephropathy, neuropathy and vasculopathy
[1–3]. Injection of AGEs into rats leads to renal changes similar to
those of diabetic nephropathy while interfering with AGE formation
reduces diabetic complications in various animal models [4–6]. AGE
formation and accumulation precedes diabetic renal disease suggest-
ing AGEs have a role in the pathogenesis of diabetic nephropathy [2].Additionally, serum and tissue AGE levels are increased in diabetic
nephropathy while AGEs cause renal cell dysfunction in vitro [7–9].
However, the precise cellularmechanismswhereby AGEs promote the
development of diabetic complications remain unknown.
AGEs regulate arachidonic acid metabolism. In neutrophils, AGEs
stimulate an enhanced respiratory burst by activating cytosolic
phospholipase A2 (cPLA2) to catalyse the hydrolysis of membrane
phospholipids to selectively release free arachidonic acid [10].
Arachidonic acid is a substrate for production of epoxyeicosatrienoic
acids by cytochrome P450 enzymes, prostaglandins by cyclooxygen-
ase and leukotrienes by 5-lipooxygenase, all of which all then
generate reactive oxygen species (ROS) [11].
Phosphatidylinositol 4,5 bisphosphate (PIP2) is a majormembrane
phospholipid that affects cellular processes such as actin cytoskeleton
modulation, membrane trafﬁcking and ion channel activity [12]. PIP2
is generated mainly via phosphorylation of phosphatidylinositol-4-
phosphate (PI4P) by phosphatidylinositol 4-phosphate 5-kinase
(PIP5K). In diabetic rats, [32P] orthophosphate incorporation into
PIP2 is preferentially increased in peripheral nerves [13] while
platelet uptake of 2-[3H] myo-inositol, a measure of phosphoinositide
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there is a paucity of studies relating to phosphoinositide metabolism
during diabetes.
Na+ K+ ATPase (NKA) is a basolateral membrane protein pump
responsible formaintaining intracellular sodium and potassiumbalance
that, in turn, regulatesmany other ion and solute transporters [15]. NKA
is regulated by many factors including hormones, neuropeptides and
glucose. In cultured endothelial and smooth muscle cells, glucose-
induced inhibition of NKA activity involves sequential activation of
protein kinase C and cPLA2 [16]. NKA is regulated acutely by its
internalisation via clathrin-mediated endocytosis, whereas transcrip-
tion and translation are involved in its long-term regulation.
NKA activity is reduced within erythrocytes of patients with type 1
and insulin-requiring type 2 diabetes and may be related to C-peptide
levels [17–23]. A few studies have also suggested a relationship
between reduced NKA activity and AGEs. Glycated proteins inhibit
NKA activity in normal platelets [24]. In diabetic rats, aminoguanidine
and OPB-9195, potent anti-glycation agents, inhibit the loss of sciatic
nerve NKA activity [25,26]. However, the mechanisms involved in
AGE inhibition of NKA activity have not been elucidated.
We examined the effects of AGEs on NKA activity in two renal
proximal tubule epithelial cell lines. We found that AGEs activated
cPLA2α and PIP5Kγ to inhibit NKA surface expression and activity.
AGEs stimulated clathrin-mediated endocytosis of NKA by a mecha-
nism that involved enhanced binding of PIP5Kγ to the clathrin
adaptor protein complex AP-2. Our studies provide the ﬁrst in vitro
evidence of a role for cPLA2α and phosphoinositide metabolism in
AGE-induced inhibition of NKA.
2. Materials and methods
2.1. Materials
Tissue culture plastics and reagents were purchased from Nunc
(Roskilde, Denmark) and Trace Biosciences (Melbourne, Australia),
respectively. All other laboratory reagents were purchased from
Sigma Corporation (St Louis, MO) unless otherwise speciﬁed.
2.2. Inhibitors
Inhibitors used in these studies and their ﬁnal concentrations are:
10 μM quinacrine dihydrochloride for PLA2, 1 μM AACOCF3 (Calbio-
chem) for cPLA2, 60 nM cPLA2α inhibitor (Calbiochem), 1 μM indo-
methacin (Calbiochem) for cox1/2, 10 nM sc-560 (Calbiochem) for cox-
1, 32 μM ns-398 (Calbiochem) for cox-2, 3.5 mM neomycin (Calbio-
chem) for PIP2, 10 μM proadifen hydrochloride and 8.9 nM HET0016
(Cayman Chemical, Ann Arbor, MI) for cytochrome P450, 2.8 μM
nordihydroguaiaretic acid (NDGA) for pan lipoxygenases, 2.5 μM
haloenol lactone(E)-6-(bromomethylene)-3-(1-naphtalenyl)-2H-tetra-
hydropyran-2-one (HELSS; Calbiochem) for Ca2+-independent PLA2,
1 μMmanoalide for secretory PLA2, 100 nM PP2 or PP3 (Calbiochem) for
Src and its negative control, respectively. Since some inhibitors were
dissolved in DMSO or ethanol, we tested the effects of these solvents in
all assays and found that they had no effect (results not shown).
2.3. AGE preparation
AGE-BSAwas prepared as described previously with modiﬁcations
[27]. Brieﬂy, BSA (10 mg/ml) or RNase (10 mg/ml) was incubated
with D-glucose (90 g/l) in 0.4 M phosphate buffer at 37 °C for 12 or
6 weeks, respectively. Preparations were lyophilised, resuspended in
water and dialysed against phosphate buffered saline (PBS) to remove
free glucose. Control BSA or RNase was prepared by identical
incubation without glucose. Glycation was assessed by characteristic
ﬂuorescence (excitation 370 nm, emission 440 nm) with a 7-28-fold
increase in ﬂuorescence of AGE-BSA compared to BSA.Methylglyoxal-BSA (MGO-BSA) was prepared as described [28].
Brieﬂy, 0.22 g BSA was incubated with or without 0.54 ml of 40 (w/
v)% methylglyoxal in 30 ml 0.4 M phosphate buffer for 24 h and then
dialysed against 30 mM ammonium bicarbonate pH 7.8 to remove
free methylglyoxal.
2.4. Cell culture
LLC-PK1 porcine and HK2 human kidney proximal tubule
epithelial cell lines were obtained from the American Tissue Culture
Collection (ATCC, Rockville, MD) [29,30]. Cells were cultured in a 5%
CO2 incubator in growth medium (GM) consisting of Dulbecco's
modiﬁed Eagle's medium (DMEM) containing 4.5 g/l glucose, 2 mM L-
glutamine, 5000 IU/l penicillin, 5 mg/l streptomycin, 125 U/l Fungi-
zone, 2.2 g/l sodium bicarbonate supplemented with 10% fetal calf
serum (FCS). For experiments under serum-free conditions, cells were
cultured in serum-free medium (SFM) consisting of DMEM with
antibiotics and glutamine supplemented with 0.5 g/l BSA.
2.5. Immunoﬂuorescence
LLC-PK1 cells were grown on glass coverslips. After incubation in
SFM overnight, cells were treated with 5–40 μM BSA or AGE-BSA for
up to 1 h in time/dose experiments. Cells were also pre-treated with
10 μM quinacrine, 1 μM AACOCF3, 1 μM indomethacin, 60 nM cPLA2α
inhibitor or 3.5 mM neomycin for 15 min and then 20 μMBSA or AGE-
BSA for 30 min. LLC-PK1 cells were incubated with 20 μg/ml PGE2 or
30 nM arachidonic acid. LLC-PK1 cells were also treated with other
AGEs to demonstrate speciﬁcity: 40 μM human glycated albumin (US
Biological, MA), 5–40 μM AGE-RNase, 5–40 μM MGO-BSA or their
respective non-glycated controls.
After ﬁxation in 3.7% paraformaldehyde/PBS for 10 min, cells were
incubated in 0.1% Triton X-100/PBS for 5 min, blocked with 1% BSA/
PBS for 15 min and stained with a 1/50 dilution in 1% BSA/PBS of anti-
PIP2 antiserum (Echelon Biosciences, Salt Lake City, UT) for 1 h at
room temperature or anti-NKAα subunit (α6F, Developmental
Studies Hybridoma Bank, University of Iowa, IA or Sigma) at a dilution
of 1/75 overnight at 4 °C. Staining with anti-mouse or anti-rabbit
rhodamine- or ﬂuoroscein-labelled secondary antibodies (Invitrogen)
was performed for 1 h at a 1/1000 dilution. After washing in PBS and
then water, slides were mounted in Permaﬂuor (Beckman-Coulter,
Marseille, France) and viewed by ﬂuorescence microscopy.
2.6. Western blotting
Cells were treated with 40 μM BSA or AGE-BSA for 24 h and cell
lysates prepared in 50 mM HEPES, 0.05 M NaCl, 0.05% Tween 20, 1%
Triton X-100, centrifuged at 12,500 rpm for 1 min and supernatants
stored at −20 °C in non-reducing sample buffer until use. Proteins
(100 μg/sample) were separated by SDS-10% PAGE, transferred to
nitrocellulose and Western blotted with anti-cox 1 (Cell Signalling,
Boston, MA), anti-cox 2 (BD Transduction Laboratories, Franklin
Lakes, NJ) or anti-β actin (1/1000) in 1% BSA/TBST (50 mM Tris base,
0.15 M NaCl, 0.1% Tween 20, pH 7.4) and proteins detected using
enhanced chemiluminescence (Supersignal West Pico; Pierce, Rock-
ford, IL) and exposure to X-ray ﬁlm for 5 min.
2.7. Thin layer chromatography
Cells grown in 6-well plates were labelled in RPMI containing
antibiotics, glutamine, 0.5 g/l BSA and 0.75 μCi/ml [3H]-myo-inositol
for 48 h. Cells were treated with BSA or AGE-BSA (40 μM) for 15 min.
Cells were scraped into 0.75 ml stop solution (methanol/HCl, 10:1).
Water (0.75 ml) and chloroform (1.5 ml) were added before vortex-
ing for 30 s and the top phase removed after centrifugation (1800×g,
5 min). Backwash (1 ml of methanol/1 M HCl, 1:1) was added and
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dryness and spotted onto oxalate-coated thin layer chromatography
plates (silica gel 60 Merck, Darmstadt, Germany) in 50 μl spotting
buffer (chloroform/methanol/10 mM HCl, 20:10:1). Plates were run
in 141 ml chloroform/110 ml methanol/23 ml water/10 ml NH4OH.
Phospholipid markers were stained in iodine vapour. Plates were
exposed to X-ray ﬁlm at −80 °C.
2.8. ROS assay
Intracellular reactive oxygen species (ROS) were detected by the
oxidation of 2′, 7′-dichloroﬂuoroscin (DCFH) to the ﬂuorescent
product 2′, 7′-dichloroﬂuoroscein (DCF). Cells were cultured subcon-
ﬂuently on coverslips in SFM for 24 h and then treatedwith 40 μMBSA
or AGE-BSA±the following inhibitors of arachidonic acid metabo-
lism: 10 μM proadifen hydrochloride, 8.9 nM HET0016, 2.8 μM NDGA
or 1 μM indomethacin. After 24 h, 1.5 μl/well of DCFH (3 mg/ml) was
added and cells incubated for 5 min at 37 °C. Cells were washed twice
with PBS and 3 ﬂuoresecent microphotographic images per treatment
were analysed using IMAGE J (http://rsb.info.nih.gov/ij/index.html).
Microscope and camera settings were identical within experiments.
2.9. 3H-arachidonic acid release
Cells in GM were cultured subconﬂuently in 24-well plates. The
mediumwas changed to SFM with 0.5 g/l fatty acid free BSA and cells
loadedwith 2.5 μCi/well of 3H-arachidonic acid (PerkinElmer, MA) for
24 h. After washing twice in Hank's buffered saline solution (HBSS),
cells were incubated in fresh SFM and pretreated with the following
inhibitors for 30 min: 10 μM quinacrine dihydrochloride, 2.5 μM
HELSS, 1 μMmanoalide or 3.5 mM neomycin. Cells were then treated
with 40 μM BSA or AGE-BSA for 1 h after which conditioned media
were collected, centrifuged at 10,000×g for 2 min and mixed with
2.5 ml scintillant (Insta-gel plus, PerkinElmer, Boston, MA) prior to
counting in a beta counter.
2.10. 4,5-dimethylthiazol-2-yl-) 2,5-diphenyltetrazolium bromide
(MTT) assay
Viable cell number was determined with a colorimetric assay which
measures the reduction of MTT by living cells to a blue, water insoluble
formazan product. Brieﬂy, LLC-PK1 cells were plated in 96-well culture
dishes in 100 μl of GM per well. After 24 h, conﬂuent cells were treated
with 40 μM BSA or AGE-BSA in SFM. After 1 or 24 h, MTT (10 μl/well of
5 mg/ml) was added to each well for 4 h at 37 °C. The medium was
removed and precipitated formazan was solubilised in 40 mM HCl/
isopropanol (100 μl/well) on a plate shaker at room temperature for
30 min. Absorbance at 540 nm was measured in a spectrophotometer.
Assays were performed in triplicate within each experiment.
2.11. NKA activity assay
Subconﬂuent cells were incubated in 12- or 24-well plates in SFM
for 24 h and pretreated with 60 nM cPLA2α inhibitor or 3.5 mM
neomycin for 15 min before treatmentwith 20 μMBSA or AGE-BSA for
30 min. To measure ouabain-sensitive [86Rb+] transport, replicate
wells were also treated with 1 mM ouabain hydrate for 30 min at
37 °C. After washing in HBSS, cells were incubated in HBSS with
10 mM HEPES and 1 μCi/ml [86Rb+] (PerkinElmer, Boston, MA) for
10 min at 37 °C. Cells were then washed three times with ice-cold
HBSS and lysed in 0.2 ml/well of 3% SDS. Cell lysates were mixed with
2.5 ml scintillant, counted in a beta counter and counts normalised to
the protein content of replicate samples. NKA-mediated transport
activity was calculated by subtracting the uptake observed in cells
preincubated with ouabain from the total uptake. [86Rb+] uptake by
LLC-PK1 and HK2 cells was linear for up to 1 h.2.12. Biotinylation of cell surface proteins
Cells were grown overnight in SFM in Petri dishes. After
pretreatment with 60 nM cPLA2α inhibitor or 3.5 mM neomycin for
15 min, cells were treated with 20 μM BSA or AGE-BSA, trypsinised
and washed three times in PBS, pH 8.0. Cells were incubated with
1 mg/ml sulfo-NHS-biotin (Thermoscientiﬁc, Rockford, IL) for 30 min
at RT, washed three times in 100 mM glycine/PBS and lysed in RIPA
buffer (50 mM Tris–HCl, 1% NP-40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EGTA, pH 7.4) containing a protease inhibitor
cocktail (Roche, IN). Lysates were centrifuged at 10,000×g for 30 s.
Protein (10 mg) was mixed with 60 μl 50% (w/v) streptavidin agarose
beads in 0.5 ml RIPA buffer and incubated overnight at 4 °C with
mixing. After washing three times in IP buffer (20 mM Tris base,
50 mM NaCl, 0.1% Tween 20 pH 7.4) containing protease inhibitor
cocktail, beads were resuspended in non-reducing sample buffer and
proteins separated by SDS-8%-PAGE. After transfer, nitrocellulose
membranes were probed with an anti-NKA α subunit antiserum (1/
5000, Santa Cruz) in 5% skim milk/PBS.
2.13. Co-immunoprecipitation
Cells were grown overnight in Petri dishes in SFM and then treated
with 60 nM cPLA2α inhibitor or 3.5 mM neomycin for 15 min prior to
addition of 20 μM BSA or AGE-BSA for 30 min. Cells were scraped into
RIPA buffer and 1 mg protein per sample was immunoprecipitated
with 1 μl anti-α-adaptin (clone 100/2) or 2.5 μl anti-β2 adaptin
(Santa Cruz) antisera overnight at 4 °C in 40 μl of a 50 (v/v)% slurry of
protein A sepharose beads (Amersham Biosciences) at 4 °C for 2 h.
After washing three times in IP buffer, non-reducing sample buffer
was added and proteins separated by SDS-8%-PAGE. After transfer,
membranes were probed with anti-NKA α subunit antiserum (1/
5000) in 5% skimmilk/PBS or anti-α-adaptin (1/5000 anti-β2 adaptin
(1/1000) antisera in 1% BSA/TBST.
2.14. PIP5Kγ siRNA
The PIP5Kγ siRNA (Dharmacon, Thermo Scientiﬁc, CO) sequence
was designed from conserved human/mouse sequences [31] but did
not knock down PIP5Kγ in porcine LLC-PK1 cells (results not shown).
We therefore used human HK2 cells for siRNA experiments. Control
non-targeting pool or PIP5Kγ siRNA (200 nM) was pre-incubated
with Dharmafectene 1 (8 μl/ml, Dharmacon) in 0.2 ml SFM for 30 min
before addition to subconﬂuent HK2 cells in 0.6 ml GM in onewell of a
6-well plate. After 48 h, cells were seeded subconﬂuently into 24-well
plates. After 24 h, the medium was changed to SFM for 24 h before
NKA activity assays were performed as described above.
2.15. Statistics
Data were analysed by t-test or ANOVA. Post-hoc analyses were
performed using Fisher's protected least signiﬁcant difference test.
Results are expressed as the mean±SEM. Experiments were repeated
between 3 to 12 times as indicated except for Fig. 1B (n=2).
3. Results
3.1. Cellular PIP2 is increased by AGE
Immunoﬂuorescencewas used to examine the localisation of PIP2 in
AGE-BSA-stimulated LCC-PK1 cells. PIP2 levels were increased ∼35% in
LLC-PK1 cells treatedwithAGE-BSA,withPIP2being found in apunctate
pattern in AGE-treated cells (Fig. 1A). Thin layer chromatography (TLC)
of [3H]-myo-inositol-labelled phospholipids in AGE-BSA-treated LLC-
PK1 cells conﬁrmed a ∼50% increase in cellular PIP2 levels (Fig. 1B).
Fig. 1. AGEs increase PIP2 levels. A LLC-PK1 cells were treated with 40 μM BSA or AGE-
BSA for 48 h. PIP2 was visualised by immunoﬂuorescence microscopy with anti-PIP2
antiserum. Experiments were performed 3 times with 3 random ﬁelds of view/
treatment. 400×. ***pb0.001 vs BSA B [3H]-myo-inositol-labelled phospholipids from
LLC-PK1 cells treated with 40 μMBSA or AGE-BSA for 15 min, were resolved by silica gel
thin layer chromatography and autoradiography. n=2. Fig. 2. AGEs induce
3H-arachidonic acid release in proximal tubule cells. 3H-arachidonic
acid-loaded A LLC-PK1 or B HK2 cells were pretreated with 10 μM quinacrine
dihydrochloride (QUIN), 2.5 μM haloenol lactone (HELSS), 1 μM manoalide (MAN) or
3.5 mM neomycin (NEO) for 30 min before treatment with 40 μM BSA (BSA) or AGE-
BSA (AGE) for 1 h. 3H-arachidonic acid released into conditioned media was assayed.
Experiments were performed 3–9 times in triplicate and results expressed as a
percentage of BSA. *pb0.05 and **pb0.01 vs BSA, #pb0.05 and ##pb0.01 vs AGE-BSA.
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AGEs induce PLA2 activity and arachidonic acid production in
neutrophils [10]. We therefore studied their effect on arachidonic acid
metabolism in proximal tubule cells.
In both LLC-PK1 and HK2 cells, AGE-BSA signiﬁcantly induced the
release of 3H-arachidonic acid compared to BSA (Fig. 2A; 133±6%,
pb0.01, n=9 and Fig. 2B; 125±6%, pb0.05, n=5, respectively).
Quinacrine, a cPLA2 inhibitor, signiﬁcantly inhibited AGE-BSA-
induced 3H-arachidonic acid release in LLC-PK1 and HK2 cells (Fig. 2A;
100±12%, pb0.01, n=8 and Fig. 2B; 92±13%, pb0.05, n=5,
respectively). However, HELSS, a Ca 2+-independent PLA2 inhibitor,
and manoalide, a secretory PLA2 inhibitor, had no effect on AGE-BSA-
induced release of 3H-arachidonic acid in LLC-PK1 cells (Fig. 2A; n=4).
These results suggest that AGEs stimulate PLA2 activity in both LLC-PK1
and HK2 proximal tubule cell lines. Furthermore, of the various PLA2
enzymes, cPLA2 appeared to be activated by AGEs.
It was recently shown that cPLA2 is activated by PIP2 [32–34]. We
therefore examined the effect of neomycin, a high afﬁnity PIP2-
binding molecule [35], on AGE-induced PLA2 activity. Neomycin
signiﬁcantly inhibited the release of 3H-arachidonic acid induced by
AGE-BSA in both LLC-PK1 and HK2 cells (Fig. 2A; 84±14%, n=4 and
Fig. 2B; 83±10%, n=5, respectively, pb0.01 for both). These results
suggest that PIP2 is involved in AGE-BSA-induced 3H-arachidonic acid
release in both proximal tubule cell lines.
3.3. AGEs stimulate arachidonic acid metabolism through
cyclooxygenase
Activation of PLA2 leads to arachidonic acid release and its
subsequent oxidation by various downstream enzymes, including
cyclooxygenases, lipooxygenases and cytochrome P450 enzymes [11].
Metabolism of arachidonic acid by these enzymes induces the
production of reactive oxygen species (ROS). We used this charac-teristic to identify downstream effectors of AGE-induced arachidonic
acid metabolism using speciﬁc inhibitors.
AGE-BSA signiﬁcantly induced ROS production compared to BSA in
both LLC-PK1 and HK2 cells (Fig. 3A; 222±29%, pb0.001, n=12 and
Fig. 3B; 159±11%, pb0.01, n=8, respectively). A similar result was
also seen in LLC-PK1 cells treated with 40 μM AGE-RNAse (results not
shown), conﬁrming that the effect was due to the glycatedmoiety and
not the speciﬁc protein.
Indomethacin, a cox 1/2 inhibitor, signiﬁcantly inhibited AGE-BSA-
inducedROS formation inboth LLC-PK1andHK2 cells (Fig. 3A; 86±13%,
n=3 and Fig. 3B; 87±12%, n=6, respectively, pb0.001 for both). In
contrast, HET0016 and proadifen, speciﬁc cytochrome P450 inhibitors,
and NDGA, a lipoxygenase inhibitor, had no effect on AGE-BSA-induced
ROS formation in LLC-PK1 cells (Fig. 3A). These results suggest that cox
activity is downstream of cPLA2 signalling induced by AGE-BSA in
proximal tubule cells.
AGE-BSA-induced ROS production was signiﬁcantly inhibited by
neomycin in both LLC-PK1 and HK2 cells (Fig. 3A; 88±18%, pb0.01,
n=3 and Fig. 3B; 72±35%, pb0.001, n=4, respectively). These
results suggest involvement of PIP2 in AGE-BSA ROS signalling in both
LLC-PK1 and HK2 proximal tubule cells.
3.4. NKA surface expression and activity is decreased by AGEs in a time-
and dose-dependent manner
LLC-PK1 cells were treated with 20 μM BSA or AGE-BSA for up to
1 h. Cells were stained for NKA α subunit protein and examined by
ﬂuorescence microscopy (Fig. 4A). In LLC-PK1 cells, NKA staining was
localised predominantly at the cell periphery [36]. Compared with
Fig. 3. Cyclooxygenase is a determinant of ROS production and arachidonic acid
metabolism by AGEs. A LLC-PK1 or B HK2 cells were treated with 40 μM BSA (BSA) or
AGE-BSA (AGE)±8.9 nM HET0016 (HET), 10 µM proadifen (PRO), 2.8 μM nordihy-
droguaiaretic acid (NDGA), 1 μM indomethacin (INDO) or 3.5 mM neomycin (NEO) for
24 h. DCFH was added and ROS production measured by ﬂuorescence microscopy and
quantiﬁed by Image J. Experiments were performed 3–12 times with 3 random ﬁelds of
view/treatment and results expressed as a percentage of BSA. **pb0.01 and ***pb0.001
vs BSA, ##pb0.01 and ###pb0.001 vs AGE-BSA.
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15 min with complete disappearance of NKA from the cell surface by
60 min. This rapid effect suggests that AGEs may stimulate NKA
endocytosis. An MTT assay was performed to exclude toxic effects of
AGEs on LLC-PK1 cells. This showed that AGE-BSA had no effect on
viable cell number compared to vehicle-treated or BSA-treated cells
after 1 or 24 h (Fig. 4B).
AGE-BSA reduced surface expression of NKA α subunit (Supple-
mentary Fig. 1) and NKA activity as assessed by [86Rb+] uptake (Fig. 5)
in a dose-dependent manner.3.5. NKA surface expression is decreased by different AGE preparations
To conﬁrm that the glycated moiety of AGE-BSA was responsible
for NKA inhibition, we tested a number of different AGE preparations.
AGE-RNase andMGO-BSA also reduced cell surface expression of NKA
(Fig. 6) (at concentrations as low as 5 μM, results not shown).
Importantly, endogenously glycated human albumin also reduced cell
surface expression of NKA, conﬁrming that this AGE action is
physiologically relevant.3.6. AGEs inhibits NKA surface expression via cPLA2α and cox 2
NKA is downregulated in various cell types in diabetes and diabetic
models [18–21,37,38]. Furthermore, arachidonic acid metabolites
inhibit NKA activity in proximal tubule cells [39–42]. We therefore
examined the effect of AGE-induced cPLA2 activity on NKA activity in
proximal tubule cells.Pre-treatment of LLC-PK1 cells with a speciﬁc cPLA2α inhibitor
reversed the inhibitory effect of AGE-BSA on NKA surface expression
(Fig. 7A). Indomethacin, an inhibitor of cox 1/2, and ns-398, a speciﬁc
cox 2 inhibitor, but not sc-560, a cox 1 inhibitor, reversed the
inhibitory effect of AGE-BSA on NKA surface expression (Fig. 7A).
Arachidonic acid and, to a lesser extent, PGE2, products of cPLA2 and
cyclooxygenase 2 respectively, also decreased expression of surface
NKA in LLC-PK1 cells. These results indicate that AGE-BSA inhibits
surface expression of NKA via a pathway involving cPLA2α and cox 2.
Both cox 1 and 2 proteins were detected in HK2 cells by Western
blotting (Fig. 7B). However, AGE-BSA increased cox 2 but not cox 1
levels (Fig. 7B). Cox 1 and cox 2 were not detected in LLC-PK1 cells
using these antibodies, most likely due to species differences.
3.7. AGEs inhibit the surface expression of biotinylated NKA and this is
reversed by cPLA2α inhibitor and neomycin
AGE-BSA did not affect total cell NKA protein levels after 24 h
treatment (Fig. 8A (i)). However, AGE-BSA decreased cell surface
expression of NKA after 30 min as determined by pulldown of
biotinylated surface proteins followed by Western blotting (Fig. 8A
(ii)). This effect was reversed by pre-treatment of cells with a cPLA2α
inhibitor or neomycin (Fig. 8B). Neomycin also reversed AGE-BSA-
inhibition of surface expression of NKA as determined by immuno-
ﬂuorescence (Fig. 8C). These experiments conﬁrm the inhibitory
effect of AGE-BSA on cell surface expression of NKA and the
involvement of cPLA2α and PIP2.
3.8. Regulation of NKA activity by AGE-induced cPLA2α and PIP2
AGE-BSA signiﬁcantly inhibited NKA activity compared to BSA
control in both LLC-PK1 and HK2 cells (Fig. 9A; 80±3%, n=12 and
Fig. 9B; 66±6%, n=7, respectively, pb0.01 for both). The cPLA2α
inhibitor reversed the AGE-BSA-induced inhibition of NKA activity in
both LLC-PK1 and HK2 cells (Fig. 9A; 116±7%, n=6, pb0.05 and
Fig. 9B; 111±12%, n=5, pb0.01, respectively). Inhibiting PIP2 with
neomycin also signiﬁcantly reversed the AGE-BSA-induced inhibition
of NKA activity in both cell lines (Fig. 9A; 96±11%, n=9 and Fig. 9B;
100±16%, n=4, respectively, pb0.05 for both).
3.9. Src inhibition reverses the AGE-induced decrease in NKA
In LLC-PK1 cells, clathrin- and caveolin-mediated endocytosis of
NKA stimulated by ouabain involves Src signalling [43–45]. AGEs
activate Src [46] so we examined a possible role for Src in AGE-
induced inhibition of NKA. AGE-BSA-induced ROS production was
signiﬁcantly lower in LLC-PK1 cells pretreated with PP2, a Src
inhibitor, than in cells treated with PP3, a negative control peptide
(Fig. 10A; 84±9%, pb0.001 vs. AGE+PP3 176±28%, n=3). Similar
ﬁndings were observed in HK2 cells (not shown). PP2 but not PP3 also
reversed the loss of surface expression of NKA by AGE as determined
by immunoﬂuorescence (Fig. 10B) and biotinylation (Fig. 10C)
studies, respectively. These results suggest that Src is involved in
AGE-BSA-induced inhibition of surface expression of NKA.
3.10. AGEs increase binding of PIP5Kγ and NKA to the α-adaptin subunit
of the clathrin adaptor protein AP-2
Endocytosis of NKA has been reported to be clathrin-dependent
[47]. We therefore examined the binding of NKA to the α-adaptin
subunit of the AP-2 clathrin adaptor complex and found that AGE-BSA
increased NKA binding after 30 min (Fig. 11A).
AGE-BSA increased cellular PIP2 levels (Fig. 1), suggesting
activation of PIP5K. All three isoforms of PIP5K, α, β and γ, bind AP-
2 or are involved in clathrin-mediated endocytosis [48–50]. However,
AP-2 and clathrin speciﬁcally bind and/or activate PIP5Kγ661 to
Fig. 4. AGEs inhibit the surface expression of NKA in a time-dependent manner and do not affect cell viability. A LLC-PK1 cells were incubated with PBS vehicle (Con), 20 μM BSA or
AGE-BSA for various time points. Cells were ﬁxed and NKA α subunit visualised by immunoﬂuorescence microscopy. 400×. Experiments were performed 3 times with 3 random
ﬁelds of view/treatment. B LLC-PK1 cells were incubated with PBS vehicle (Con), 40 μM BSA or AGE-BSA for 1 (black) or 24 (grey) hours. Viable cell numbers were determined by
MTT assay. Experiments were performed 3 times and expressed as a percentage of BSA control.
924 M.A. Gallicchio, L.A. Bach / Biochimica et Biophysica Acta 1803 (2010) 919–930regulate endocytosis [51–53]. We therefore studied whether PIP5Kγ
was involved in the stimulation of NKA endocytosis by AGE-BSA. AGE-
BSA enhanced binding of PIP5Kγ, in addition to NKA, to the AP-2 α-Fig. 5. AGEs inhibit NKA activity in a dose-dependent manner. LLC-PK1 cells were
incubated with 10–40 μM BSA (black) or AGE-BSA (grey). After washing, cells were
incubated in HBSS with 10 mM HEPES and 1 μCi/ml [86Rb+] for 10 min at 37 °C. Cell
lysates were counted in a beta counter and counts normalised for protein content.
Experiments were performed 3–4 times with 3 replicates/treatment and results
expressed as a percentage of BSA for a given treatment. *pb0.05 and ***pb0.001 vs.
BSA, #pb0.05 and ##pb0.01 vs. 10 μM AGE-BSA.adaptin subunit (Fig. 11A), but AGE-BSA had no effect on binding of
PIP5Kγ to the AP-2 β2-adaptin subunit (Fig. 11B).
3.11. PIP5Kγ is essential for AGE induced inhibition of NKA activity
To determine the role of PIP5Kγ in AGE-induced inhibition of NKA
activity, we used siRNA to knock down expression by ∼90% (Fig. 12A).
AGE-BSA signiﬁcantly inhibited NKA activity in control siRNA-
transfected HK2 cells compared to BSA (Fig. 12B; 59±8%, n=7,
pb0.001). In contrast, AGE-BSA had no signiﬁcant effect on NKA
activity in PIP5Kγ siRNA-transfected cells (Fig. 12B; 84±4%, n=7).
These results suggest that AGE-BSA-induced inhibition of NKA activity
in HK2 cells is dependent on PIP5Kγ.
4. Discussion
AGEs are implicated in the development of diabetic nephropathy.
Disruption of NKA activity is a feature of a number of renal pathologies.
In particular, NKAactivity is decreased inmany tissues includingkidney,
sciatic nerve and red blood cells in diabetic patients and animals.
Erythrocyte NKA activity is decreased in patients with types 1 and
insulin-requiring type 2 diabetes andmay be related to C-peptide levels
[17–23]. In patients with uncontrolled type 1 diabetes, this decrease
correlates with hyperglycemia and is corrected by its normalisation. In
streptozotocin (STZ)-diabetic rats, NKA activity is decreased by∼40% in
erythrocytes, sciatic nerve and kidney [37]. NKA activity is also reduced
Fig. 6. Various AGEs inhibit the surface expression of NKA. LLC-PK1 cells were incubated
with PBS control (Con), 40 μM RNase, AGE-RNase, BSA, MGO-BSA, human normal or
glycated albumin for 30 min. Cells were ﬁxed and NKA α subunit visualised by
immunoﬂuorescence microscopy. 400×. Experiments were performed 3 times with 3
random ﬁelds of view/treatment.
Fig. 7. Role of cPLA2α and cox 2 in AGE-induced inhibition of surface NKA. A LLC-PK1
cells were pre-incubated with 60 nM cPLA2α inhibitor, 1 μM indomethacin, 10 nM sc-
560, or 32 μM ns-398 for 15 min. and then 20 μM BSA or AGE-BSA for 30 min. LLC-PK1
cells were also treated with 0.2% ethanol vehicle (Con), 30 nM arachidonic acid or
20 μg/ml PGE2. Cells were ﬁxed and NKA α subunit visualised by immunoﬂuorescence
microscopy 400×. Experiments were performed 3 times with 3 random ﬁelds of view/
treatment. B HK2 cells were treated with 40 μM BSA or AGE-BSA for 24 h. Lysates were
collected and proteins separated by SDS-10%-PAGE and Western blotting performed
with cox 1 or cox 2 and β actin antisera. Experiments were performed 3 times.
925M.A. Gallicchio, L.A. Bach / Biochimica et Biophysica Acta 1803 (2010) 919–930in the medullary thick ascending limb in STZ-diabetic rats after
12 weeks [38]. NKA itself is glycated in kidney and erythrocytes and is
thought to contribute to reduced lens ion transport that occurs during
the development of diabetic cataracts [54,55]. Our studies suggest an
additional mechanism for decreased NKA activity in proximal tubule
cells during diabetes, namely that AGEs inhibit NKA activity by
increasing the activities of cPLA2α and PIP5Kγ to reduce cell membrane
expression of NKA via endocytosis. Importantly, endogenously glycated
human albumin also decreased cell surface NKA expression, illustrating
the physiological relevance of our ﬁndings.
The physiological activation of PLA2 and cyclooxygenase pathways
is important for normal renal function as these modulate salt and
water reabsorption [56]. Renal eicosanoid levels are altered in
diseases such as diabetes and may contribute to nephropathy. AGEs
stimulate cPLA2 activity in neutrophils [10]. We found that AGEs
induced cPLA2α activity in proximal tubule cells as indicated by (i)
stimulation of 3H-arachidonic acid release and its attenuation by
quinacrine, (ii) prevention of AGE-BSA inhibition of cell membrane
NKA by a cPLA2α inhibitor, (iii) inhibition of cell membrane NKA by
arachidonic acid and (iv) attenuation of AGE-BSA-induced inhibition
of NKA activity by a cPLA2α inhibitor. Our ﬁndings are consistent with
the modulation of NKA by arachidonic acid and its metabolites that
has been shown previously in various nephron segments [39–42].
High glucose levels increase PLA2 activity and PGE2 generation in
mesangial cells and increase PGE2 and decrease NKA activity in
cerebral endothelial cells [57,58]. In contrast, other studies have
shown that AGE-BSA inhibits prostacyclin production in human
endothelial cells and PGE2 secretion by human proximal tubular cells
[59,60]. These contrasting ﬁndings suggest that AGEs and glucosemay
have different effects or that effects are cell-type speciﬁc.
We found AGEs induced cyclooxygenase activity as indicated by
the sensitivity of AGE-induced ROS formation to indomethacin.
Involvement of cox 2 was subsequently identiﬁed by the (i)
attenuation of AGE-BSA inhibition of cell membrane expression of
NKA by ns-398, (ii) inhibition of cell membrane expression of NKA by
PGE2 and (iii) upregulation of cox 2 but not cox 1 protein by AGE-BSA.In monocytes, cox 2 mRNA is increased by AGEs, high glucose or
diabetes, while overexpression of RAGE, the receptor for AGEs, is
associated with enhanced cox 2 protein expression in diabetic plaque
macrophages [61–63]. However, high glucose inhibits NKA activity in
pancreatic β-cells via the lipoxygenase pathway [64] which shows
that different pathways could play a role in the regulation of NKA
activity in different cells. Other stimuli, including endothelin, also
inhibit NKA activity in proximal tubules via cox [41,65–67] whereas
parathyroid hormone and angiotensin II both inhibit NKA activity in
the proximal tubule via the cytochrome P450 pathway [39,40].
Additionally, PGE2 inhibition of NKA surface expression appeared less
complete than that by arachidonic acid, suggesting the possible
involvement of other cox metabolites such as TXA2, PGI2, PGF2 or
PGD2. This possibility requires further investigation.
AGEs increased cellular PIP2 levels in the current study. Neomycin,
which sequesters and inhibits PIP2 [35], inhibited both AGE-induced
Fig. 8. AGEs inhibit surface expression of NKA: role of cPLA2α and PIP2. A LLC-PK1 cells
were incubated with 20 μMBSA or AGE-BSA (i) for 24 h andwhole cell lysates collected
or (ii) for 30 min and cell surface proteins biotinylated, isolated with streptavidin
sepharose beads, separated by SDS-10%-PAGE, blotted and probed with anti-NKA α
subunit antiserum. Experiments were performed 3 times. B LLC-PK1 cells were pre-
incubated with 60 nM cPLA2α inhibitor or 3.5 mMneomycin for 15 min and then 20 μM
BSA or AGE-BSA for 30 min. Cell surface proteins were biotinylated and analysed as in A
(ii). Experiments were performed 3 times. C LLC-PK1 cells were incubated with 40 μM
BSA or AGE-BSA±3.5 mM neomycin (NEO) for 30 min. Cells were ﬁxed and NKA α
subunit visualised by immunoﬂuorescence microscopy 400×. Experiments were
performed 3 times with 3 random ﬁelds of view/treatment.
Fig. 9. AGEs inhibit NKA activity: role of cPLA2α and PIP2. A LLC-PK1 or B HK2 cells were
pre-incubated with 0.01% ethanol vehicle, 60 nM cPLA2α inhibitor (cPLA2α) or 3.5 mM
neomycin (neo) for 15 min and then 20 μM BSA (black), AGE-BSA (grey) or an equal
volume of PBS (white) for 30 min. After washing, cells were incubated in HBSS with
10 mM HEPES and 1 μCi/ml [86Rb+] for 10 min at 37 °C. Radioactivity was counted in a
beta counter and normalised for protein content. Experiments were performed 4–12
times with 3 replicates/treatment and results expressed as a percentage of BSA control.
**pb0.01 vs. BSA, #pb0.05 and ##pb0.01 vs AGE-BSA.
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cPLA2 dramatically increases its activity and membrane association
[32–34], it is possible that AGEs also stimulate cPLA2 activity by
activating PIP5Kγ and upregulating PIP2 levels.
Liu et al. found that Src activity is essential for the inhibition of
surface expression of NKA in LLC-PK1 cells by ouabain via clathrin- and
caveolin-mediated endocytosis [43–45]. We found that inhibiting Src
reversed the AGE-induced decrease of surface expression of NKA in
LLC-PK1 cells as determined by immunoﬂuorescence and biotinyla-
tion. Pertinently, AGEs activate Src in other cell types [46]. Liu et al.
found Src was recruited to caveolin, clathrin and endosomes upon
ouabain stimulation [44,45].We showed that AGEs increase binding of
NKA to the α-adaptin subunit of the clathrin endocytic adaptor
complex, AP-2, implicating the involvement of clathrin-mediated
endocytosis. Future studies aimed at conﬁrming our hypothesis that
AGEs inhibit NKA by clathrin-mediated endocytosis require showing
that subcellular localisation of NKA to early and late endosomes and
clathrin vesicles. Possible Src recruitment to clathrin vesicles also
warrants further study.
Clathrin-mediated endocytosis of some cargoes requires PIP2-
dependent membrane recruitment of AP-2 adaptor complexes [68].
We found increased binding of PIP5Kγ to the AP-2 α adaptin subunit
and also found that neomycin prevented AGE-induced inhibition of
NKA surface expression and activity. Neomycin inhibits clathrin/AP-2
recruitment to the cell membrane [69–71], suggesting it may have
interfered with AGE-induced NKA endocytosis in this manner.The α- and μ2-adaptin subunits of the α,β2,μ2,σ2 tetrameric AP-2
complex contain PIP2 binding sites which allows them to interact
with the plasma membrane and regulate clathrin-mediated endocy-
tosis [68,69,72]. PIP2 elevated by PIP5Kβ and γ isoforms is implicated
in AP-2 recruitment to the cell membrane [49,50]. In contrast,
PIP5Kγ661 enhances AP-2-regulated endocytosis through its μ2-
subunit without affecting cellular PIP2 levels [53]. We found AGEs
increased overall cellular levels of PIP2 and increased binding of
PIP5Kγ to the AP-2 α-adaptin subunit. PIP2 may be involved in
corecognition of protein cargo by AP-2, AP-2 relocalisation to the cell
membrane [49,50,72] or exert direct effects on increasing clathrin pit
formation [73].
Several groups have shown that AP-2 itself activates PIP5Kγ
[50,53,74]. We observed increased binding of PIP5Kγ to the AP-2 α-
adaptin subunit, which is consistent with previous studies showing
co-immunoprecipitation of endogenous PIP5K with α- and β-
adaptins, although this interaction was thought to be indirect
[74,75]. Others have shown that PIP5K is activated by AP-2 after its
association with cargo proteins via the μ2-adaptin subunit [75],
whereas PIP5Kγ661 is activated by AP-2 through β2- or μ2-adaptins
[53,74].
Isoform speciﬁc functions of PIP5K contribute to speciﬁc cell
functions at the plasma membrane such as the formation of focal
adhesions and clathrin adaptor recruitment and receptor internalisa-
tion [49,76]. PIP5Kβ regulates constitutive endocytosis while α and γ
isoforms regulate stimulated endocytosis in nonneuronal and
Fig. 10. Src inhibition reverses the inhibitory effect of AGE on NKA. LLC-PK1 cells were pretreated with 100 nM PP3 or PP2 for 15 min, then treated with 40 μMBSA (BSA) or AGE-BSA
(AGE) for 30 min. A DCFH was added and ROS production measured by ﬂuorescence microscopy and quantiﬁed by Image J. Experiments were performed 3 times with 3 random
ﬁelds of view/treatment and results expressed as a percentage of BSA+PP3. **pb0.01 vs. BSA+PP3, ###pb0.001 vs. AGE-BSA+PP2. B Cells were ﬁxed and NKA α subunit
visualised by immunoﬂuorescence microscopy. 400×. Experiments were performed 3 times with 3 random ﬁelds of view/treatment. C Cell surface proteins were biotinylated,
isolated with streptavidin sepharose beads, separated by SDS-8%-PAGE, blotted and probed with anti-NKA α subunit antiserum. Experiments were performed 3 times.
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PIP5K and endocytosis have been reported in kidney cells or in
relation to a speciﬁc pathological process such as diabetes. However,
PIP5Kα enhanced endocytosis of the epithelial sodium channel in a
PIP2-dependent manner in cultured kidney collecting duct cells [48].
To our knowledge, our studies are the ﬁrst to show PIP5Kγ function
during endocytosis in a non-neuronal cell line.
Is there evidence that elevated cellular PIP2may be pathological in
diabetes? There are a number of diseases in which PIP2 levels are
elevated [79]. One of these is Lowe syndrome, which is characterised
by proximal tubule reabsorption defects and dysregulated clathrin-
mediated membrane trafﬁcking as a result of dysfunctional phos-
phoinositide metabolism [79]. PIP2 levels are elevated in proximal
tubule cells from patients with Lowe syndrome due to OCRL, a
mutated inositol 5-phosphatase. Circulating levels of lysosomal
enzymes are also increased, suggesting dysregulated lysosomal
vesicular trafﬁcking [79,80]. In patients with diabetes, levels of the
urinary lysosomal enzyme, N-acetyl B glucosaminidase (NAG), amarker of proximal tubular injury, correlates with glycated haemo-
globin levels [81]. We observed that AGE-BSA increased NAG release
by ∼40% in LLC-PK1 cells (results not shown), and, together with the
above observations in Lowe syndrome, suggests that this may be
related to elevated cellular PIP2 levels. Whether diabetic nephropathy
is a PIP2-mediated disease warrants further study.
4.1. Conclusions
In summary, our results demonstrate that AGEs stimulate cPLA2,
cyclooxygenase and PIP5Kγ/PIP2 activities to inhibit NKA (Fig. 13).
AGEs are shown to inhibit NKA surface expression and activity in a
time- and dose-dependent manner and this is reliant on cPLA2α,
cyclooxygenase 2, Src and PIP2. Inhibition of NKA activity by AGEs is
due to increased binding of NKA to the α-adaptin subunit of the
clathrin endocytic adaptor complex, AP-2, which would enhance NKA
endocytosis from the cell surface. AGEs also increase binding of
PIP5Kγ to α-adaptin. Enhanced PIP2 from PIP5Kγ activity may
Fig. 11. AGEs increase binding of NKAα subunit and PIP5Kγ to theα-adaptin subunit of
the AP-2 adaptor complex. LLC-PK1 cells were incubated with PBS vehicle (Con), 40 μM
BSA or AGE-BSA for 30 min. Adaptin proteins in cell lysates were immunoprecipitated
with α-, or β2-adaptin antisera and protein A sepharose beads. Normal mouse IgG was
used as control (Cl). Proteins were separated by SDS-8%-PAGE, blotted and probed with
A anti-α-adaptin, -PIP5Kγ and -NKA α antisera or B anti-β2-adaptin and -PIP5Kγ
antisera. Experiments were performed 3–4 times.
Fig. 12. PIP5Kγ siRNA reverses AGE inhibition of NKA activity. A HK2 cells were
transfected with control or PIP5Kγ siRNA for 48 h. Proteins in cell lysates were
separated by SDS-8%-PAGE and Western blotting performed with anti-PIP5Kγ and β-
actin antisera. B HK2 cells transfected with vector control (black) or PIP5Kγ (grey)
siRNA were incubated with PBS vehicle (con), 40 μM BSA or AGE-BSA for 30 min. After
washing, cells were incubated in HBSS with 10 mM HEPES and 1 μCi/ml [86Rb+] for
10 min at 37 °C. Radioactivity was counted in a beta counter and normalised for protein
content. Experiments were performed 7 times with 3 replicates/treatment and results
expressed as a percentage of BSA control. ***pb0.001 vs. BSA.
Fig. 13. Postulated pathways by which AGEs inhibit NKA activity in proximal tubule
cells.
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formation, enhance cargo recognition by AP-2 or stimulate cPLA2α
activity. These studies are the ﬁrst to link AGEs to dysregulation of
phosphoinositide metabolism and the ﬁrst to link a speciﬁcpathological process such as diabetes to increased PIP5K activity
and enhanced endocytosis of NKA cargo.
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